Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Go back to Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 34.01 +0.33 (0.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.68 | 52 Week High | $5.17 | |||
| Open | $33.36 | 52 Week Low | $0.94 | |||
| Day High | $34.60 | P/E | N/A | |||
| Day Low | $33.30 | EPS | $0.00 | |||
| Volume | 261,506 | |||||
